Production (Stage)
Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.00060.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -42.27% | 58.04% | 82.76% | 80.58% | 78.74% |
| Total Depreciation and Amortization | 94.19% | -3.79% | -52.57% | -50.04% | -48.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.42% | -81.36% | -95.69% | -94.17% | -92.65% |
| Change in Net Operating Assets | 100.78% | 108.95% | 127.69% | -248.47% | -196.81% |
| Cash from Operations | 27.49% | 54.06% | 72.69% | 44.13% | 8.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6,200.00% | 98.30% | 100.09% | 100.03% | 100.01% |
| Cash from Investing | -57,800.00% | 83.15% | 100.09% | 100.03% | 100.01% |
| Total Debt Issued | -- | -- | -- | -73.64% | -56.64% |
| Total Debt Repaid | 19.98% | 48.91% | 68.95% | 30.85% | -44.10% |
| Issuance of Common Stock | 22.35% | -32.18% | -69.10% | -31.77% | 45.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -301.21% | -89.17% | 75.58% | 17.46% | -215.63% |
| Cash from Financing | -22.68% | -55.94% | -78.91% | -50.81% | -19.45% |
| Foreign Exchange rate Adjustments | -120.14% | -88.69% | -71.27% | 65.52% | 329.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 582.99% | 2.66% | -71.11% | 56.72% | 103.60% |